Collaborations & Alliances

Forge Therapeutics Achieves CARB-X Milestone

Is now eligible to receive as much as $4 million in additional support to advance novel IV/Oral LpxC antibiotic

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Forge Therapeutics, Inc., a biotechnology company developing medicines targeting metalloenzymes, has achieved technical milestones and received notice from CARB-X to proceed with the next stage of product funding for its novel IV/Oral LpxC antibiotic to treat urinary tract infections.  In March 2017, CARB-X selected Forge as one of the first recipients of a cost-sharing award to advance promising antibacterial candidates through the early stages of development. To date, Forge has earned $4.8 ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters